To investigate the polymorphism of human minor histocompatibility (mH) antigens, PBLs from 23 Japanese individuals and 25 German individuals with HLA-B35 were studied by using four human mH antigen-specific, HLA-B35-restricted CTL clones. The CTL clones killed PHAstimulated PBLs from all 23 Japanese individuals. On the other hand, they killed the PHAstimulated PBLs from 19 of 25 German individuals and partially killed the PHA-stimulated PBLs from three German individuals (CTL weakly sensitive cell line); those from another three individuals (CTL-resistant cell line) were not killed by the CTL clones. All of three CTL weakly sensitive cell lines carry HLA-B*3503 molecules, whereas the three CTL-resistant cell lines carry HLA-B*3502, B'3507, and B'3508 molecules. The cytotoxicity of the CTL clones for three CTL weakly sensitive cell lines was enhanced by stimulation of human mH peptides isolated from HLA-B*3501 molecules purified from CIR.-B*3501 cells. Small amounts of human mH peptides were isolated from B'3503 molecules purified from these three CTL weakly sensitive cell lines. Taken together, these results indicate that weak recognition by the CTL clones of three CTL weakly sensitive cell line results from a small amount of the human mH peptides presented by B'3503 molecules. The CTL-resistant cell line carrying B'3507 loaded with the human mH peptides was killed by four CTL clones, whereas the cell lines carrying B'3502 or B'3508 loaded with the peptides were not. The human mH peptides were not isolated from B'3507 molecules purified from the cell lines expressing this subtype, whereas small amounts of the human mH peptides were isolated from B'3502 and B'3508 molecules purified from the cell lines expressing these subtypes. These results indicate that failure of the CTL recognition of the cell line carrying B'3507 is due to a lack of human mH antigens in this cell line. The failure of the CTL recognition of the cell lines carrying B'3502 and B'3508 is not explained by only the amount of the human mH peptides binding to these B35 subtype molecules because the amount of the human mH peptides eluted from B* 3502 and B'3508 molecules purified from the cell lines carrying these B35 subtypes is almost the same as that eluted from B'3503 molecules purified from the cell lines carrying B'3503. It is suspected that the conformational structure of the human mH peptides bound to these HLA-B35 subtype molecules changes and initiates a lack of the recognition of the CTL clones. The currrent study showed that the human mH antigens are conserved beyond race and that recognition by human mH antigen-specific T cells is critically influenced by the subtypes of HLA class I molecules.
M inor histocompatibility (mH) 1 antigens have not . been studied in detail even though they are very important in transplantation, since incompatibility of these antigens induces the rejection of grafts in organ transplantation and graft versus host disease in bone marrow transplantation (1). In these diseases, mH-specific cytotoxic T cells but not specifc antibodies are induced (2-7). T cells recognize mH antigens in association with MHC antigens (4, 5, 7).
Recent studies have demonstrated that mH antigens are presented as peptides by MHC class I molecules in the mouse (8) (9) (10) and human (11) (12) (13) .
It is suspected that mH peptides are derived from selfproteins or endogenously integrated viral protein, and the peptides are transported into the endoplasmic reticulum via transporters after they are generated in the cytoplasm as peptides derived from self-proteins and viral proteins (14) (15) (16) (17) (18) (19) . Peptides take part in the assembly of MHC class I molecules in the endoplasmic reticulum (20, 21) . Assembled MHC class I molecules are transported to the cell surface and are recognized by T cells.
In the mouse '~50 mH antigen genes have been mapped using congenic strains, and a limited polymorphism is known (1) . In contrast, genes encoding human mH antigens have not been mapped, and the polymorphism of human mH antigens is not known. A recent study of population genetics using HLA-A2-restricted human mH antigen-specific CTL clones (22) has shown that the phenotype frequencies of three human mH antigens are 69, 16, and 7%.
There are many HLA subtypes that are distinguished by alloreactive CTL clones, biochemical analysis using twodimensional electrophoresis, or molecular analysis using sequencing of the genes encoding HLA antigens. For example, 12 subtypes of HLA-A2 have been reported. Only three of these subtypes can be distinguished by serology (23) . Since amino acid substitutions found among the subtypes affect the presentation of virus antigens to specific T cells (24) (25) (26) (27) (28) , it is assumed that a given subtype of HLA class I antigen cannot present human mH peptides to specific T cells. Thus, population genetic analysis using mere recognition by CTL clones may not reflect the frequencies of mH antigens in a given population.
To investigate phenotype frequencies of human mH antigens in detail, we analyzed the frequencies of human mH antigens that are recognized by an HLA-B35-restricted CTL clone using an acid elution method for peptides and sequencing of HLA-B35 genes. Moreover, the current study demonstrated a molecular mechanism for the presentation of human mH peptides by HLA class I molecules.
Materials and Methods
Cells. PBLs from 23 Japanese individuals and 25 German individuals with HLA-B35 were collected. HLA haplotypes of these individuals were serologically determined. These PBLs were stimulated with PHA. PHA-induced T cells were cultured in RPMI 1640 medium with 10% FCS and 50 U/ml recombinant human IL-2, 1 Abbreviation used in this paper: mH, minor histocompatibility. and the cells were used for CTL assays. EBV-transformed cell lines from German individuals, EBV-transformed self-B cell line from a recipient of HLA-identical renal grafts (Pt cells) (7), EBVtransformed B cell lines from a donor (Dn-2) (7), and Hmy2CIR (CIR) cells were maintained in RPMI 1640 medium with 10% FCS. T2 cells expressing HLA-B*3501 (T2-B*3501) were previously generated (29) , and they were cultured in RPMI 1640 medium with 10% FCS.
Transfection of the HLA-B*3502 Gene into C1R Cells. The HLA-B'3502 genomic gene was previously cloned (30) . This gene was cotransfected with a hygromycin-resistance gene into HLA-A, B null C1R cells as previously described (31) . CIR cells expressing HLA-B*3502 (CIR-B*3502) were selected by flow cytometry using SFR8-B6 anti-HLA-Bw6 mAb (32) . C1R cells expressing B'3501 (CIR-B*3501) were previously generated (33) . CIR-B*3502 and CIR-B*3501 cells were cultured in RPMI 1640 medium with 10% FCS and 0.15 mg/ml hygromycin B.
Flow Cytometry Analysis. Approximately 5 x 105 cells, suspended in 50 ml of PBS with 2% FCS, were incubated with 50 ml of appropriately diluted SFRS-B6 anti-HLA-Bw6 or 4D12 anti-HLA-B5, B35 cross-reacting antigen mAb (34) for 30 rain on ice. After two washes with PBS containing 2% FCS, the cells were incubated with 50 ml of FITC-conjugated F(ab')2 goat anti-mouse Ig (Silenus Laboratories, Hawthorne, Australia) at a dilution of 1:40 for 30 min on ice. The cells were washed three times with PBS containing 2% FCS, and the mean intensity of fluorescence was measured by a FACStar (Becton Dickinson, Mountain View, CA).
CTL Clones. Four human mH antigen-specific, HLA-B35-restricted CTL clones, NH-5.2, NH-5.3, NH-5.5, and NH-5.9, were previously generated and characterized (7) . These CTL clones were maintained by repeated stimulations with the EBV-transformed B cell line Dn-2 at 1-wk intervals and feeding with RPMI 1640 medium supplemented with 2 mM g-glutamine, 10% FCS, and 50 U/ml human recombinant IL-2 every third day.
CTL Assay. Target cells (5 x 10 s) were incubated for 60 or 90 min with 100 #Ci of Na2SaCrO4 in PBS and washed three times with RPMI 1640 medium containing 10% FCS. Target cells (5 x 1@ per well) were added to serial dilutions of effector cells at E/T ratios of 4:1-0.5:1, and the mixtures were incubated for 4 or 6 h at 37~ in 96-well round-bottom microtiter plates (Nunc, Roskilde, Denmark). The supematants were collected and analyzed with a gamma counter. Spontaneous saCr release was determined by measuring the counts per minute in the supernatant in wells containing only target cells. The maximum release was determined by measuring the release of SlCr from target cells in the presence of 2.5% Triton X-100. The specific lysis was calculated using the following formula: percent specific lysis = [(cpm~p -cpmspn)/ (cpmm~ --cpm,p,)] x 100, where cpm~p is the counts per minute in the supernatant in wells containing target and effector cells, cpmsp, is the spontaneous release, and cpm ..... is the maximum release.
Isolation and Characterization of HLA-B35 cDNA Clones. Total cellular RNA was extracted from EBV-transformed cell lines by standard methods (35) . mRNA was reverse transcribed using random hexamers (first strand DNA synthesis kit; Pharmacia LKB Biotechnology Inc., Piscataway, NJ,). cDNA was then PCR amplified with HLA-B locus-specific primers, as described (36) . Amplified DNA was subcloned in the SalI/HindIII sites of pUC18. Recombinant clones were identified by colony hybridization to an HLA class I cDNA probe, pHLA-2 (37). Double-stranded DNA plasmids were sequenced by the chain termination method using Sequenase 2.0 (United States Biochemical Corp., Cleveland, OH) and exon- EBV-transformed B cells expressing four HLA-B35 subtypes were lysed in 2 ml of 1.5% NP-40 detergent in 10 mM PBS containing 1 mM PMSF, 10 mg/ml trypsin inhibitor A, 10 -S M pepstatin A, 10 -5 M leupeptin, and 10 -4 M iodoacetamide. The resulting suspension was stirred for 30 rain at 4~ and centrifuged for 30 min (1,800 g). The resulting supernatant was incubated with CNBractivated Sepharose CL4B beads (Pharmacia), to which 4D12 or W6/32 mAb had been covalently coupled. The sample was again rotated six times at 4~ to precipitate FILA class I molecules. After washing in 10 mM PBS containing 0.1% NP-40, loaded beads were subjected to 50 mM diethylamine (pH 11.5). Eluted sample were lyophilized, resolved in 2 ml of 0.1% TFA, and separated in a Superpac Pep S reverse-phase HPLC column. Each fraction (1 ml) was collected and lyophilized for CTL assay.
CTL Assay.for B Cell Lines Stimulated with Isolated Human mH
Peptides. Dried HPLC fractions were dissolved in 200 #1 of PBS. 50 #1 of this solution was added to 50 #1 of the medium containing 5 x 103 StCr-labded B cell lines in round-bottom wells of a 96-well microplate. After incubation for 60 rain at 37~ 100 #1 of the medium containing 2 x l& CTL clones was added to yield a final volume of 200 #1 (4:1 E/T ratio). Plates were then incubated for 6 h at 370C. The supematants were collected and analyzed with a gamma counter.
Results
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" Percent specific lysis at a 1:1 E/T ratio. More than 20% of percent specific lysis was evaluated as positive killing (boldface). 2039 Beck et al.
B*3501-restricted Human mH Antigen-specific CTL Clones.
Our previous study (7) showed that four mH antigen-specific, HLA-B*3501-restricted CTL clones (NH-5.2, NH-5.3, NH-5.5, and NH-5.9) killed B cell lines derived from all of five individuals with HLA-B35. These findings suggest that the human mH antigens recognized by these CTL clones are very well conserved among Japanese or other populations and that only members of this family lack these antigens. To identify the distribution of human mH antigens in populations, we examined the recognition by the CTL clones of a panel of cells derived from Japanese and German individuals. As shown in Table 1 Table 2 ). Taken together, these data suggest that the human mH antigens recognized by these four CTL clones may be less conserved within the Caucasian population than the Japanese population, though they are very well conserved in the Japanese population. It is speculated that poor recognition of the CTL clones for three cell lines (the CTL weakly sensitive cell lines) or lack of recognition of three cell lines (the CTL-resistant cell lines) may be due to low or even absent expression of HLA-B35 antigens on the cell lines, respectively. To exclude this possibility, we examined the surface expression of HLA-B35 antigens on these cell lines by flow cytometry with 4D12 anti-BS, B35 mAb. As shown in Table 3 , all of the cell lines expressed HLA-B35. Mean intensities of fluorescence of cell lines 13159 and 19635 were higher than those of other cell lines expressing HLA-B35. This is explained by the fact that mAb 4D12 cross-reacts with HLA-B15 (34) . The mean intensities of fluorescence of the other five cell lines (13.9 to 29.0) were the same as those of six CTDsensitive cell lines (10.5 to 28.4). These results indicate that weak or lacking recognition by the CTL clones of these CTL weakly sensitive and CTL-resistant cell lines does not result from low or absent expression of HLA-B35 molecules. Three cell lines, 12405, 13159, and 21254, were partially killed by four CTL clones with a 4-h incubation and an E/T ratio of 1:1. The killing of these cell lines was enhanced with a 6-h incubation (Fig. 1) , suggesting that HLA-B35 molecules on these cell lines may present a small amount of the human mH peptide to CTL clones. (Fig. 2) . B'3503 (39), B'3507, and B'3508 differ from B'3501 only by a single amino acid substitution at residues 116, 16, and 156, respectively. Residue 156 is a peptide-binding site in the o~2 helix, and residue 16 is in the outer loop of the B sheet (Fig. 2) . 
Sequence of HLA-B3 5 Genes in
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Binding of the Human mH Peptide to HLA-B35 Antigens on Three CTL-resistant Cell Lines and Three CTL I, Veakly Sensitive Cell Lines.
Our recent studies showed that four human mH antigen-specific, HLA-B*3501-restricted CTL clones recognize the human mH peptides presented by HLA-B*3501 molecules (11, 12, 29) . Therefore, the results of experiments using CIR-B*3502 and the sequence data of the HLAoB35 gene in CTL-resistant cell lines and CTL weakly sensitive cell lines suggest that B'3502 molecules in the 18514 cell line and B'3508 in the 22338 cell line do not bind the human mH peptides, whereas B'3503 molecules in three CTL weakly sensitive celt lines bind a relatively small amount of the human mH peptides. To clarify this possibility, we investigated direct binding of the human mH peptides to HLA-B35 subtype molecules on these cell lines. Naturally occurring human mH peptides were isolated by reverse-phase HPLC from HLA- B'3501 molecules that were purified from C1R-B*3501 cells. The HPLC fraction containing human mH peptides was detected using four CTL clones as previously described (11) and was used as the source of human mH peptides. The cells expressing HLA-B35 subtypes were cultured at 26~ overnight and then used as target cells for four CTL clones after stimulation with human mH peptides. As shown in Fig. 4 from the cell line lysates was separated by reverse-phase HPLC.
Isolation of Naturally Occurring Human mH Peptides from CTL resistant Cell Lines and CTL Weakly Sensitive Cell Lines,
Fractions 29-32 were tested for recognition of the NH-5.5 clone using Pt cells as the target, since the human mH peptides that the CTL clones recognized were isolated in fraction 30 or 31 (11) . A small amount of the human mH peptides was detected in fraction 30 from extracts of the CTL-resistant cell line 22338, whereas no human mH peptides were isolated from extracts of other cell lines (Fig. 5) . Since three CTL weakly sensitive cell lines were partially killed by the CTL clones, it is suspected that the amounts of peptides isolated from these cell lines are too small to be detected by the CTL assay using Pt cells as target cells. Therefore, we used HLA-B*3501-transfected T2 cells (T2-B*3501) as target cells in the assay in order to detect a small amount of the human mH peptides because the T2 transfectants express many empty HLA-B35 molecules. Pt and T2-B*3501 cells were stimulated with titrated fraction 30 containing the human mH peptides from CIR-B'3501 cells and then tested by using the NH-5.5 clone. As shown in Fig. 6 , the capacity of the CTL clone to detect the human mH peptides was enhanced 10-fold when T2-B*3501 cells were used as target cells. Fractions 29-32 were again tested for recognition by the NH-5.5 clone using T2-B*3501 cells (Fig. 7) . The human mH peptides were detected in fraction 31 from three CTL weakly sensitive cell lines as well as the 18514 and 22338 cell lines. In contrast, no human mH peptides were isolated from the 20073 cell line. These results demonstrated that only the 20073 cell line does not possess human mH antigens. 2043 Beck et al. (Fig. 7) . This does not demonstrate direct isolation of the specific human mH peptides from these HLA-B35 subtype molecules. Therefore, we attempted to isolate the specific human mH peptides from purified HLA-B35 subtype molecules. HLA-B35 molecules were isolated from six cell lines expressing HLA-B35 sybtypes as well as from Pt and Dn-2 cells using Sepharose beads coupled with 4D12 anti-B5, B35 mAb. Peptides bound to these HLA-B35 molecules were isolated by reverse-phase HPI.C after purified HLA-B35 molecules were resolved in 0.1% TFA solution. Fractions 29-32 were tested for recognition by the NH-5.5 clone using T2-B*3501 cells as target cells (Fig. 8) . The specific human mH peptides were again isolated from HLA-B*3502, B'3503, and B'3508 molecules purified from the cell lines expressing these HLAoB35 subtypes. The amount of the specific peptides isolated from these subtype molecules was significantly smaller than that that from HLA-B*3501 mole- HLA-B * 3508 differs from HLA-B* 3501 by a single amino acid substitution at position 156. Since this residue is one of the peptide-binding sites facing the E pocket, it is assumed that the substitution of arginine for leucine affects the binding of human mH peptides. The current study shows that the amount of the human mH peptides duted from B'3508 molecules purified from the 22338 cell line is less than that from B'3501 molecules purified from Dn-2 cells. However, the amount of human mH peptides bound to HLA-B*3508 molecules seems to be sufficient for the recognition by the CTL clones, since it is significantly more than that from B'3503 molecules purified from the cell lines expressing this B35 subtype that were partially killed by the CTL clones. A previous study using an HLA-A2 mutant at position 156 (42) demonstrated that 24 of 25 HLA-A2-restricted, influenza virus matrix peptide-specific CTL lines could not recognize HLA-A2 mutant at residue 156 loaded with the peptide, whereas one CTL line recognized it. This study suggested that the amino acid substitution at residue 156 of the HLA-A2 molecule affects the recognition by the specific CTL clones but does not inhibit binding of the peptide to the HLA class I molecules. The current study together with a previous study using HLA-A2 mutant suggests that the substitution at residue 156 changes the conformational structure of the peptides bound to the HLA class I molecules, resulting in a lack of recognition of the CTL clones.
We recently demonstrated that the substitution of glutamic acid for valine at residue 152 of HLA-B*3501 does not affect the binding of the human mH peptides recognized by CTL clones NH-5.2, NH-5.3, NH-5.5, and NH-5.9, but it does abrogate recognition by these CTL clones (29) . Since residue 152 is also one of the residues forming the E pocket, it supports the idea that the substitution at the position of the ot helix forming the E pocket changes the conformational structure of the human mH peptides bound to the HLA class I molecules. Moreover, the substitution of asparagine for asparaginic acid at residue 114 facing the E pocket and that of tyrosine for serine at residue 116 facing the F pocket seem to change the conformational structure of the human mH peptides bound to HLA-B35 molecules. The amount of human mH peptide bound to HLA-B*3502 molecules purified from the 18514 cell line is more than that bound to HLA-B*3503 molecules purified from three CTLs weakly sensitive cell lines, whereas the CTL clone partially killed PBLs expressing B'3503 but not those expressing B'3502. Taken together, these observations of HLA-B*3502 and B'3508 suggest that T cells recognize a conformational structure of the human mH peptides bound to HLA-B35 molecules.
HLA-B*3507 differs from B'3501 by a single amino acid substitution at position 16. It is thought that this residue hardly affects peptide binding because residue 16 is on the outer loop of the B sheet. Therefore, it is assumed that cell line 20073 expressing HLA-B*3507 molecules does not possess the human mH antigens containing the specific epitope recognized by the CTL clones. Indeed, the current study showed that the specific human mH peptides are not isolated from this cell line, whereas HLA-B*3507 molecules can bind the specific peptides.
In this study, we demonstrated that the human mH peptides recognized by four CTL clones are presented by HLA-B35 molecules in all 23 Japanese individuals and in 24 of 25 German individuals. Since there is no difference in recognition by these CTL clones for a panel ofceUs expressing HLA-B35 and Pt cells loaded with the peptides eluted from the cells expressing HLA-B35 subtypes, it is suspected that these CTL clones recognize a single peptide. However, it will be confirmed only by identification of the peptides recognized by four CTL clones. Further identification of the peptides recognized by four CTL clones is necessary to darify the number of human mH peptides recognized by these CTL clones. The current study demonstrated that at least one human mH antigen is conserved in the Japanese and German populations.
Since human mH antigens are recognized by T cells but not by antibodies, their polymorphism was studied only in the specific T cells. This study showed that five of six cell lines that are not killed by the CTL clones possess the human mH peptides. Thus, a simple analysis using killing activity by CTL clones cannot reveal the frequency of a human mH antigen in the population. Analyses of HLA subtypes and human mH peptides are also required to estimate the frequency of human mH antigens in detail. We showed here that only 1 of 25 German people and 23 Japanese people lacks the human mH antigen containing the specific T cell epitopes. This indicates that the human mH antigens are conserved beyond race. The current study also demonstrated that HLA-B'3501-restricted, human mH antigen-specific CTL clones failed to recognize human mH peptides presented by other HLA-B35 subtype molecules. This indicates that precise typing of HLA subtype is particularly required in bone marrow transplantation in which incompatibility of human mH antigens induces graft rejection and graft versus host disease.
